BCL2 and autoimmune hemolytic anemia: New small molecules such as Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the BCL-2 inhibitor venetoclax, and the Phosphoinositol-3-kinase (PI3K) inhibitor idelalisib, are rarely associated with AIHA.